OBIO CAAP Company: ImmunoBiochem Wins at RESI San Francisco

CAAP company ImmunoBiochem, which is solving the problem of tumor heterogeneity by targeting unique proteins enriched in the secretomes of cancer cells with Antibody Drug Conjugates (ADCs) won 2nd place at the highly competitive RESI San Francisco Innovation Challenge.

Read the press release

Previous
Previous

OBIO CAAP Company: ImmunoBiochem Wins at RESI San Francisco Innovation Challenge

Next
Next

OBIO Pre-CAAP Company: Trexo Robotics are Finalists in the 7th Annual Canadian Innovation Awards